Cytokinetics, Incorporated
NASDAQ: CYTK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert I. Blum
- Employees
- 498
- Headquarters
- South San Francisco, United States
- IPO year
- 2004
- Market cap
- $9.8B
- Website
- https://www.cytokinetics.com
Loading CYTK…
Loading profile data…Frequently asked questions about CYTK
What does Cytokinetics, Incorporated (CYTK) do?
Cytokinetics, Incorporated is an advanced biopharmaceutical company dedicated to the research, development, and commercialization of therapies that modulate muscle function. These novel compounds aim to address debilitating diseases. The core of their pipeline consists of small molecule drug candidates specifically designed to influence muscle p...
Where does CYTK trade?
Cytokinetics, Incorporated (CYTK) trades on the NASDAQ Global Select.
What sector is CYTK in?
Cytokinetics, Incorporated (CYTK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cytokinetics, Incorporated?
Robert I. Blum is the chief executive officer of Cytokinetics, Incorporated (CYTK).
Where is Cytokinetics, Incorporated headquartered?
Cytokinetics, Incorporated is headquartered in United States.
Does CYTK pay a dividend?
Cytokinetics, Incorporated (CYTK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYTK go public?
Cytokinetics, Incorporated (CYTK) completed its initial public offering in 2004.